Biocon has refinanced its debt, which could reduce finance costs by 20-30 basis points. Positive growth drivers include Syngene and Generics, with further potential in the biosimilars business ...

Are you looking to further reduce debt? What is your strategy? Debt reduction is a priority for Biocon Group and Biocon Biologics. Last fiscal, we reduced $250 million in acquisition debt.

Biocon’s subsidiary, Biocon Biologics Limited (BBL), has announced the completion of its first year as a fully integrated ...

Biocon had a 54.45 percent stake in Syngene International as of September 30. The funds raised will go a long way towards helping the company repay the debt it had taken on for the acquisition of ...

Biocon Pharma, a subsidiary of Biocon, got China’s approval for Tacrolimus capsules (0.5mg, 1mg, 5mg). The immunosuppressant helps prevent organ rejection in transplant patients and strengthens ...

On December 10, the markets saw a block trade involving ₹706 Crore in shares of Contract Development Manufacturing Organisation (CDMO) participant Syngene International, with promoter Biocon ...

For Biocon to a certain extent ... on the EBITDA front is something to be watched out for. Obviously, the net debt has ...

The funds raised will go a long way towards helping the company repay the debt it had taken on for the acquisition of Viatris Inc's biosimilars portfolio for over $3 billion. Biocon-Serum deal ...

The deal is valued at Rs 366 crore. The acquisition will be partially funded through debt financing. Biocon Limited retains eight position amongst Top 10 Employers in global biotech, pharma ...